Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis, Sacramento, CA, USA Abstract: During the menopausal transition, women experience a number of symptoms due to declining estrogen levels, includin...
Guardado en:
Autores principales: | Wurz GT, Kao CJ, DeGregorio MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83b025405eab4bb59a699d7f34d71146 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy
por: Jonasson AF, et al.
Publicado: (2021) -
Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study
por: Fianu Jonasson A, et al.
Publicado: (2020) -
Vaginal microbiota during the menopausal transition: the role of lactobacilli
por: Yulia E. Dobrokhotova, et al.
Publicado: (2021) -
Evisceración vaginal tras tratamiento con radioterapia e histerectomía abdominal
por: González B,Isabel, et al.
Publicado: (2015) -
Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis
por: Yen-Pin Lin, et al.
Publicado: (2021)